financetom
Business
financetom
/
Business
/
National Bank of Canada Says Franco-Nevada's 2024 Guidance Unchanged
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
National Bank of Canada Says Franco-Nevada's 2024 Guidance Unchanged
Apr 11, 2024 8:10 AM

10:52 AM EDT, 04/11/2024 (MT Newswires) -- National Bank of Canada said Wednesday that Franco-Nevada Corp.'s ( FNV ) Investor Day provided additional context on the company's previously released information. The bank said Franco-Nevada ( FNV ) provided no changes to its outlook based on the company's 2024 and long-term guidance, which remained unchanged.

Franco-Nevada ( FNV ) maintained a 2024 guidance of 480,000 to 540,000 ounces of gold equivalent. (incl. 360,000 to 400,000 GEOs from precious metal assets) including commencement from Tocantinzhinho, Greenstone, Posse (Mara Rosa) and Salares Norte. This compares to an NBF Estimate of 530,000 GEOs (at FNV budgeted commodity prices) including 400,850 GEOs from precious metals. The guidance assumes no contributions from Cobre Panama. FNV maintained long-term guidance of 540,000 to 600,000 GEOs by 2028 compared to NBF Estimates of 605,370 GEOs (excl. Cobre Panama) at FNV commodity price deck.

In a Cobre Panama update, FNV will continue with their arbitration proceedings. Panama national elections will be held in early May where a new government may ultimately be willing to negotiate First Quantum's contract for operating the mine.

The bank left Franco-Nevada ( FNV ) a sector perform rating and with a $190.00 price target.

"FNV remains a staple name in the gold sector, offers unparalleled portfolio diversification and maintains a strong financial position," the bank said.

Price: 165.01, Change: -1.32, Percent Change: -0.79

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Broadridge's Securities Finance, Collateral Management Platform Implemented by Americas Executions
Broadridge's Securities Finance, Collateral Management Platform Implemented by Americas Executions
Oct 10, 2024
05:41 AM EDT, 10/10/2024 (MT Newswires) -- Broadridge Financial's (BR) Securities Finance and Collateral Management technology platform has been implemented by Americas Executions, the latter said Thursday. Financial terms weren't disclosed. The platform provides front-to-back software-as-a-service offering for securities finance, security lending, and collateral trading, the company added. Americas Executions said it will use the platform to manage its securities...
Franklin Resources September Assets Under Management Decline
Franklin Resources September Assets Under Management Decline
Oct 10, 2024
05:48 AM EDT, 10/10/2024 (MT Newswires) -- Franklin Resources ( BEN ) reported Wednesday preliminary month-end assets under management of $1.679 trillion as of Sept. 30, down from $1.682 trillion a month earlier. The company said long-term net outflows of $22.4 billion were in part offset by positive markets. For the quarter ended Sept. 30, the company said net outflows...
Market Chatter: Boeing Facing Protracted Labor Action
Market Chatter: Boeing Facing Protracted Labor Action
Oct 10, 2024
05:58 AM EDT, 10/10/2024 (MT Newswires) -- Boeing ( BA ) could face a protracted labor action as striking members of the International Association of Machinists and Aerospace Workers say they are in it for the long haul, Reuters reported Thursday, citing an interview with lead negotiator Jon Holden. The parties remain in a deadlock after negotiations fell through Tuesday,...
Alvotech Says AVT03 Marketing Application Accepted by European Medicines Agency
Alvotech Says AVT03 Marketing Application Accepted by European Medicines Agency
Oct 10, 2024
05:57 AM EDT, 10/10/2024 (MT Newswires) -- Alvotech ( ALVO ) said Thursday the European Medicines Agency has accepted a marketing application for AVT03, its proposed biosimilar to Prolia and Xgeva. The confirmatory studies of AVT03 showed a similar efficacy, safety, immunogenicity and pharmacokinetics to Prolia and Xgeva in postmenopausal women with osteoporosis, the company said. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved